CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 12/25/21
Implied Volatility Surging for CRISPR Therapeutics (CRSP) Stock OptionsZacks Investment Research • 12/13/21
CRISPR Therapeutics AG (CRSP) Down 17.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/03/21
CRISPR Therapeutics AG's (CRSP) CEO Sam Kulkarni at Piper Sandler 33rd Annual Virtual Healthcare Conference (Transcript)Seeking Alpha • 12/02/21
Crispr Therapeutics: An Interesting Company That Has Reconnected With A Fair ValuationSeeking Alpha • 12/02/21
CRISPR Therapeutics' (CRSP) CEO Samarth Kulkarni on 4th Annual Evercore ISI HealthCONx ConferenceSeeking Alpha • 12/01/21
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignanciesGlobeNewsWire • 11/22/21
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 DiabetesGlobeNewsWire • 11/16/21
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR TherapeuticsThe Motley Fool • 11/04/21